RxDoctor Payments Data

Ameesh Dara, DO

Nephrology · Saint Louis, MONPI 1417367244

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Amgen at 56.0% of the total. Reporting peaked in 2023 at $4,276 and has fallen 96.0% since, to $171 in 2025.

$7,116in general payments, 2019–2025

Across 128 payments — averaging $55.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AstraZeneca$821
  • Otsuka America Pharmaceutical, Inc.$551
  • Mallinckrodt Enterprises LLC$354
  • Nxstage Medical, Inc.$221
  • Bayer$170
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$2,37533%
  • Travel & lodging$92313%
  • Food & beverage$3,43348%
  • Education$3855%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,116 in reported general payments places this provider in the 85th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$134,240
Medicare patients
184
Services billed
1,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate11$3,193
Calcium Acetate30$1,793
Sevelamer Carbonate16$1,574
Bumetanide18$801
Carvedilol26$326
Atorvastatin Calcium23$257
Amlodipine Besylate21$165
Losartan Potassium18$109
Spironolactone18$99
Furosemide24$62
Allopurinol19$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$821$3,19311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 253 nephrology providers in Missouri.

Other nephrology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →